News

High commendation for DMTC collaboration in National Innovation Awards

A collaborative project demonstrating sovereign industrial capability gains and delivering sustainment cost reductions for Defence received a High Commendation at the AVALON 2023 National Innovation Awards.

DMTC Limited and its industry and research partners are pairing advances in the use of existing additive manufacturing technologies, such as laser additive deposition, with novel technology developments to successfully repair worn or degraded airframe components. (more…)

Key steps to advance vaccine manufacturing technology

Emerging Australian biotech company Sementis is engaging with Health Security Systems Australia and Australian universities to enhance the ability of its existing vaccine manufacturing technology to pivot, scale and rapidly deploy in response to emerging health and biosecurity challenges.

The initial 12-month collaboration with Sementis will draw on the company’s long-standing partnership with the University of South Australia as well as expert researchers from the Biomedicine Discovery Institute at Monash University and The Australian National University.

(more…)

Interns join DMTC for Land Forces 2022

On the second day of Land Forces 2022, DMTC Ltd hosted a delegate day for its Industry Capability Development program. DMTC’s Delegate Day provided attendees with an opportunity to meet other program participants from across Australia and hear how DMTC’s leadership of capacity-building and technology transfer activities closely aligns with Defence’s focus on increasing opportunities for Australian industry, with the aim of better supporting the warfighter. (more…)

Rapid diagnostic platform technology commended at Land Forces 2022

A DMTC-led collaboration has been awarded a High Commendation as part of the prestigious Land Forces 2022 Innovation Awards on the first day of the Exposition in Brisbane.

The award of a high commendation recognises the effort of Health Security Systems Australia (a division of DMTC), in partnership with BioCifer Pty Ltd, CSIRO and academic partners University of the Sunshine Coast and The University of Queensland, to develop a rapid diagnostic platform technology that is accelerating point-of-care detection of bacteria and viruses, and providing a capability advantage for deployed ADF personnel. By focussing on addressing the need to build Australian capability in rapid, accurate and low-resource disease detection, this novel technology aims to detect and diagnose multiple pathogens including COVID-19, Nipah virus, Dengue virus, Hendra virus, and bacteria possessing antimicrobial resistance (AMR), which are of concern to both civilian and ADF personnel who travel or are deployed overseas. (more…)